Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine +/- Azithromycin for COVID-19 Inpatients
NCT04361461Phase 3Withdrawn
- Sponsor
- Apsen Farmacêutica
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Apsen Farmacêutica. Primary endpoint: Individual response rate at 14 days. Planned start Apr 2020; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04361461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361461.